Sheryl Stevenson

home

authors

sheryl-stevenson


John J. Grande, CFP, and John S. Grande, CFP, of Grande Financial Services, discuss how having a solid financial plan in place can ease anxiety amid the ongoing coronavirus pandemic and ahead of a potential second wave, advice to ophthalmologists contemplating retirement, as well as the financial repercussions the economy may face heading into 2021.


Podcasts

John J. Grande, CFP, and John S. Grande, CFP, discuss why ophthalmologists should be focusing on having a financial plan ahead of a second wave in the ongoing pandemic.  

Planning for financial safety in uncertain times

Ophthalmologist Holocaust survivor shares his story

A story of survival, as told by one ophthalmologist

In this latest EyePod episode, John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his experience. 

EyePod: Ophthalmologist shares Holocaust survival story


Ted Leng, MD, MS, associate professor of ophthalmology with the Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Leng is joined by Steven D. Schwartz, MD, the Ahmanson Professor of Ophthalmology and chief-retina division with Stein Eye Institute, UCLA. Schwartz highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data,” which highlights the impact of the coronavirus disease 2019 pandemic on intravitreal injection usage.

Videos

Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."


(AAO) Applying impact of real-world data on day-to-day practice


Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of some of the company’s podium presentations from the Port Delivery System with ranibizumab to the novel pipeline molecule, faricimab.

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

Sheryl Stevenson

Articles

EyePod: Ophthalmologist shares Holocaust survival story

(AAO) Applying impact of real-world data on day-to-day practice

(AAO) Genentech provides update on presentations, product portfolio

Planning for financial safety in uncertain times